Grzegorz Sumara, Olga Sumara, Jason K. Kim, Gerard Karsenty 

Slides:



Advertisements
Similar presentations
Volume 10, Issue 4, Pages (October 2009)
Advertisements

Volume 9, Issue 3, Pages (March 2009)
Volume 12, Issue 1, Pages (July 2010)
Volume 20, Issue 3, Pages (July 2017)
Volume 3, Issue 1, Pages (July 2002)
Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism
Volume 7, Issue 4, Pages (April 2008)
Volume 17, Issue 5, Pages (May 2013)
Volume 15, Issue 4, Pages (April 2012)
Volume 3, Issue 5, Pages (May 2006)
Volume 16, Issue 10, Pages (September 2016)
Volume 20, Issue 4, Pages (October 2014)
Volume 26, Issue 2, Pages e3 (August 2017)
Volume 12, Issue 6, Pages (December 2010)
Irs1 Serine 307 Promotes Insulin Sensitivity in Mice
Volume 24, Issue 6, Pages (December 2016)
Volume 14, Issue 2, Pages (August 2011)
Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism
Volume 17, Issue 4, Pages (April 2013)
Volume 18, Issue 2, Pages (August 2013)
Volume 6, Issue 3, Pages (September 2007)
Volume 11, Issue 4, Pages (April 2010)
Volume 21, Issue 11, Pages (December 2017)
IRS1-Independent Defects Define Major Nodes of Insulin Resistance
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 26, Issue 5, Pages e3 (November 2017)
Volume 17, Issue 5, Pages (May 2013)
Volume 15, Issue 5, Pages (May 2012)
Volume 18, Issue 5, Pages (November 2013)
Volume 18, Issue 13, Pages (March 2017)
Volume 11, Issue 4, Pages (April 2010)
Volume 10, Issue 1, Pages (July 2009)
Volume 25, Issue 6, Pages e8 (June 2017)
Protection against High-Fat-Diet-Induced Obesity in MDM2C305F Mice Due to Reduced p53 Activity and Enhanced Energy Expenditure  Shijie Liu, Tae-Hyung.
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Regulation of Hepatic Energy Metabolism and Gluconeogenesis by BAD
Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  Xiongjie Jin, Demetrius.
Volume 23, Issue 6, Pages (June 2016)
Volume 9, Issue 5, Pages (May 2009)
Volume 17, Issue 8, Pages (November 2016)
Volume 24, Issue 1, Pages (July 2016)
Volume 6, Issue 4, Pages (October 2007)
Volume 10, Issue 5, Pages (November 2009)
Volume 10, Issue 1, Pages (July 2009)
Volume 8, Issue 4, Pages (October 2008)
Volume 25, Issue 4, Pages e4 (April 2017)
Volume 5, Issue 5, Pages (May 2007)
Volume 1, Issue 4, Pages (April 2005)
Volume 22, Issue 2, Pages (August 2015)
Syntaxin 4 Overexpression Ameliorates Effects of Aging and High-Fat Diet on Glucose Control and Extends Lifespan  Eunjin Oh, Richard A. Miller, Debbie C.
Volume 14, Issue 4, Pages (October 2011)
Prevention of Steatosis by Hepatic JNK1
High-Fat Diet Triggers Inflammation-Induced Cleavage of SIRT1 in Adipose Tissue To Promote Metabolic Dysfunction  Angeliki Chalkiadaki, Leonard Guarente 
Volume 134, Issue 6, Pages (September 2008)
Volume 8, Issue 5, Pages (November 2008)
Volume 15, Issue 2, Pages (February 2012)
Volume 7, Issue 6, Pages (June 2008)
Volume 22, Issue 2, Pages (August 2015)
Volume 27, Issue 4, Pages e4 (April 2018)
Mice with AS160/TBC1D4-Thr649Ala Knockin Mutation Are Glucose Intolerant with Reduced Insulin Sensitivity and Altered GLUT4 Trafficking  Shuai Chen, David.
Volume 20, Issue 4, Pages (October 2014)
Volume 6, Issue 4, Pages (October 2007)
Volume 26, Issue 5, Pages e3 (November 2017)
Volume 4, Issue 5, Pages (November 2006)
Volume 7, Issue 4, Pages (May 2014)
Volume 14, Issue 2, Pages (August 2011)
Volume 26, Issue 2, Pages e3 (January 2019)
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice  Jun Yoshino, Kathryn F. Mills,
Evidence against a Physiologic Role for Acute Changes in CNS Insulin Action in the Rapid Regulation of Hepatic Glucose Production  Christopher J. Ramnanan,
Volume 16, Issue 3, Pages (September 2012)
Presentation transcript:

Gut-Derived Serotonin Is a Multifunctional Determinant to Fasting Adaptation  Grzegorz Sumara, Olga Sumara, Jason K. Kim, Gerard Karsenty  Cell Metabolism  Volume 16, Issue 5, Pages 588-600 (November 2012) DOI: 10.1016/j.cmet.2012.09.014 Copyright © 2012 Elsevier Inc. Terms and Conditions

Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 GDS Is Required for Fasting-Induced Lipolysis (A) Relative expression levels of Tph1 in duodenum from mice fasted for indicated times (n ≥ 5). (B and C) Plasma levels of serotonin (B) and glucagon (C) in mice fasted for indicated times (n ≥ 5). (D–G) Plasma levels of glycerol (D), FFAs (E), β-hydroxybutyrate (F), and triglycerides (G) in mice of indicated genotypes fasted for indicated times (n ≥ 7). (H) Percent of fat content in fed and fasted mice of indicated genotypes measured by magnetic resonance imaging (MRI) (n ≥ 5). (I) Percent of fat content loss during 48 hr fasting in relation to initial fat content of each animal; average of five mice of Tph1f/f and Tph1gutΔ/Δ genotype. (J) Epigonadal fat pad weight to body weight ratio in fed and fasted Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 6). (K) Histology of fat pad from fed and 48 hr fasted Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 5). (L–N) Average size of adipocytes from fat pad of fed and 48 hr fasted Tph1f/f and Tph1gutΔ/Δ mice (L, n ≥ 5). Plasma levels of glycerol (M) and FFAs (N) in mice with implanted placebo or serotonin-releasing pellets fasted for indicated time (n ≥ 8). (O and P) Plasma levels of glycerol (O) and FFAs (P) at indicated time points after i.p. injection of serotonin (doses in mg/kg BW) (n ≥ 5). Data represented as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 GDS Favors Lipolysis through Htr2b Receptor Expressed in Adipocytes (A and B) Glycerol (A) and FFAs (B) release from mouse epigonadal fat explants stimulated with indicated doses of serotonin (n ≥ 5). (C) Relative expression of indicated serotonin receptors in adipose tissue of fed and fasted mice. (D–F) Plasma levels of glycerol (D), FFAs (E), and β-hydroxybutyrate (F) in mice lacking Htr2b in adipose tissue (deletion by aP2-Cre, indicated on graphs Htr2bfatΔ/Δ [aP2]) fasted for indicated times (n ≥ 20). (G and H) Plasma levels of glycerol (G) and FFAs (H) in mice lacking Htr2b in adipose tissue (deletion by Adiponectin-Cre, indicated on graphs Htr2bfatΔ/Δ [Aq]) fasted for indicated times (n ≥ 6). (I) Epigonadal fat pad weight to body weight ratio in fed and fasted Htr2bf/f and Htr2bfatΔ/Δ (aP2) mice (n ≥ 12). (J and K) Glycerol (J) and FFA levels (K) in Htr2bf/f and Htr2bfatΔ/Δ (aP2) mice implanted with serotonin-releasing pellets. (L and M) Glycerol (L) and FFAs (M) release from epigonadal fat explants isolated from Htr2bf/f and Htr2bfatΔ/Δ (aP2) mice and stimulated with 50 μM serotonin or 1 μM isoproterenol (n = 5). (N) Western blot analysis of expression and activation of indicated proteins in fat explants isolated from Htr2bf/f and Htr2bfatΔ/Δ (aP2) mice and stimulated with 50 μM serotonin. (O) Western blot analysis of expression and activation of indicated proteins in fat pads isolated from Htr2bf/f and Htr2bfatΔ/Δ (aP2) mice fasted for 48 hr. Data are represented as mean ± SEM, ∗p < 0.05, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 3 GDS Promotes Gluconeogenesis in Liver (A) Glycerol-evoked glucose production in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 8). (B) Pyruvate tolerance test in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 8). (C) Glycerol tolerance test in mice with implanted placebo or serotonin-releasing pellets (n ≥ 8). (D) Glycerol-evoked glucose production in Tph1f/f and Tph1gutΔ/Δ mice injected with serotonin (10 mg/kg BW) 90 min before the test (n ≥ 7). (E and F) Hepatic glucose production (E) and glucose infusion rate (F) during hyperinsulinemic-euglycemic clamp in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 7). (G) Production of glucose from indicated substrates by primary hepatocytes stimulated with indicated doses of serotonin or 100 nM glucagon (n = 5). (H) Glucose tolerance test in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 7). (I) Plasma insulin levels during glucose tolerance test in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 7). (J) Glucose tolerance test in mice with implanted placebo or serotonin-releasing pellets (n ≥ 8). (K) Glucose tolerance test in Tph1f/f and Tph1gutΔ/Δ mice injected with serotonin (10 mg/kg BW) 90 min before the test (n ≥ 7). (L) Glucose uptake in primary hepatocytes stimulated with indicated doses of serotonin. (M) Glucose tolerance test in Tph1+/+ and Tph1−/− mice (n ≥ 3). Data are represented as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 4 GDS Promotes Gluconeogenesis in Liver by Signaling through the Htr2b Receptor (A) Relative expression of indicated serotonin receptors in primary mouse hepatocytes. Red color indicates receptors for which the transcript was detected. (B) Relative expression of indicated serotonin receptors in liver of fed and fasted mice. (C) Glycerol tolerance test in Htr2bf/f and Htr2bliverΔ/Δ mice (n ≥ 7). (D) Pyruvate tolerance test in Htr2bf/f and Htr2bliverΔ/Δ mice (n ≥ 7). (E) Production of glucose from indicted substrates by hepatocytes isolated from Htr2bf/f and Htr2bliverΔ/Δ mice and stimulated by 50 μM serotonin (n = 5). (F) Glycerol tolerance test in Htr2bf/f and Htr2bliverΔ/Δ mice implanted with placebo or serotonin-releasing pellets (n ≥ 6). (G and H) Normalized FBPase (G) and G6Pase (H) activity in livers of fasted Htr2bf/f and Htr2bliverΔ/Δ mice (n ≥ 6). (I and J) Normalized FBPase (I) and G6Pase (J) activity in isolated hepatocytes stimulated with indicated doses of serotonin (n ≥ 3). Data are represented as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 5 GDS Inhibits Glucose Uptake in Liver by Signaling through the Htr2b Receptor (A) Glucose tolerance test in Htr2bf/f and Htr2bliverΔ/Δ mice (n ≥ 8). (B) Glucose tolerance test in Htr2bf/f and Htr2bliverΔ/Δ mice implanted with placebo or serotonin-releasing pellets (n ≥ 6). (C) Relative glucose uptake in Htr2b-deficient hepatocytes stimulated with 50 μM serotonin. (D) Immunofluorescence with antibodies against Glut1 and Glut2 on primary hepatocytes of indicated genotypes stimulated with 50 μM serotonin. (E) Western blot analysis of expression of indicated proteins in livers from fasted Htr2bf/f and Htr2bliverΔ/Δ mice. (F) Normalized glucokinase activity in livers of fasted Htr2bf/f and Htr2bliverΔ/Δ mice. Data are represented as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 6 Inhibition of GDS Synthesis Protects from Type 2 Diabetes (A) Insulin tolerance test in Tph1f/f and Tph1gutΔ/Δ mice (n ≥ 7). (B) Insulin tolerance test in Htr2bf/f and Htr2bfatΔ/Δ mice (n ≥ 12). (C) Body weight gain of Tph1f/f and Tph1gutΔ/Δ mice fed normal or high-fat diet (n ≥ 5). (D and E) Plasma levels of glycerol (D) and FFAs (E) in mice of indicated genotypes fed normal (ND) or high-fat diet (HFD), fasted for 4 hr (n ≥ 5). (F–H) Pyruvate (F), insulin (G), and glucose tolerance tests (H) in Tph1f/f and Tph1gutΔ/Δ mice on indicated diets (n ≥ 5). (I) Plasma serotonin concentrations in mice treated with vehicle or LP533401 inhibitor (n ≥ 8). (J) Body weight gain of mice treated with vehicle or LP533401 inhibitor, fed ND or HFD (n ≥ 8). (K and L) Plasma levels of glycerol (K) and FFAs (L) in mice treated with vehicle or LP533401 inhibitor fed ND or HFD and fasted for 4 hr (n ≥ 7). (M–O) Pyruvate (M), insulin (N), and glucose tolerance tests (O) in mice treated with vehicle or LP533401 inhibitor fed ND or HFD (n > 7). Data are represented as mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Cell Metabolism 2012 16, 588-600DOI: (10.1016/j.cmet.2012.09.014) Copyright © 2012 Elsevier Inc. Terms and Conditions